hers semaglutide fda Hims? Hers? It's Novo Nordisk's Market Now What to know about Hers'
Description
Diabetes Res Clin Pract 93: 317327, 2011
Confirmation requires capillary blood glucose measurement during symptomatic episodes, ideally demonstrating glucose levels below 3.0 mmol/L with symptom resolution following carbohydrate intake (Whipple's triad)
A 2024 FDA safety review identified reports of suicidal thoughts in some users, though causality remains unclear
Weight regain after stopping semaglutide is possible and common , especially if old habits return
Absorption heavily influenced by stomach conditions
